0ND5.LSE H Lundbeck A/S
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- 0.02%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Mar 2022.
Is 0ND5.LSE undervalued?
Graham numberThe Graham number of H Lundbeck A/S cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
H Lundbeck A/S fundamental analysis
No fundamental analysis for H Lundbeck A/S yet.
H Lundbeck A/S stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About H Lundbeck A/S
H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Ci…
Full company profileH Lundbeck A/S financial statements
2022 annualized: Fiscal year 2022 is not finished. Income statement and cash flow are annualized from 1 quarter up to Mar 31, 2022, the balance sheet is the latest quarter. Figures change when the annual report is published.
H Lundbeck A/S annual financial statements (DKK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 15.6B | 17.2B | 18.1B | 17.0B | 17.7B | - | - |
| Gross Profit | 11.6B | 13.4B | 14.7B | 13.2B | 13.5B | - | - |
| Operating Income | 2.29B | 4.41B | 5.30B | 3.15B | 1.99B | - | - |
| Net Income | 1.21B | 2.62B | 3.91B | 2.31B | 1.58B | - | - |
| Balance Sheet | |||||||
| Total Assets | 20.2B | 19.8B | 23.0B | 38.1B | 36.0B | - | - |
| Total Liabilities | 10.5B | 7.58B | 8.76B | 21.4B | 19.1B | - | - |
| Shareholders' Equity | 9.69B | 12.2B | 14.3B | 16.8B | 17.0B | - | - |
| Cash & Short-term Investments | 2.22B | 3.68B | 6.64B | 3.01B | 3.92B | - | - |
| Total Debt | 1.71B | 57.0M | 72.0M | 7.50B | 5.81B | - | - |
| Cash Flow | |||||||
| Operating Cash Flow | 3.13B | 4.05B | 5.98B | 2.61B | 3.84B | 2.27B | - |
| Capital Expenditure | 342M | 725M | 300M | 356M | 364M | 410M | 0.00 |
| Ratios | |||||||
| ROE | 12.5% | 21.5% | 27.4% | 13.8% | 9.3% | - | - |
| ROA | 6.0% | 13.3% | 17.0% | 6.1% | 4.4% | - | - |
| Net Profit Margin | 7.7% | 15.2% | 21.6% | 13.6% | 8.9% | - | - |
| Debt to Equity | 0.18x | 0.00x | 0.01x | 0.45x | 0.34x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
H Lundbeck A/S dividends
H Lundbeck A/S has not paid dividends in the last 9 fiscal years.
Last stock split: 4:1 on Jun 10, 2022.
Who owns H Lundbeck A/S
- Insiders 0.10%
- Institutions 80.63%
- Public & others 19.27%
- Free float 304M
H Lundbeck A/S company profile
- Company name
- H Lundbeck A/S
- Ticker
- 0ND5.LSE
- ISIN
- DK0061804770
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Oil, Gas & Consumable Fuels
- Employees
- 5,000
- Fiscal year end
- December
- Address
- Ottiliavej 9, Valby, Denmark, 2500
- Phone
- 45 36 30 13 11
- Website
- lundbeck.com
About H Lundbeck A/S
H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomatic neurogenic orthostatic hypotension; Onfi for epilepsy; Sabril for refractory complex partial seizures and infantile spasms; Ebixa for dementia, Azilect for Parkinson's disease; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol for psychosis. In addition, the company develops Eptinezumab for migraine prevention; Eptinezumab, which is in phase 3 clinical trial for cluster headache; Lu AG09222, which is in phase 2 clinical trial for migraine prevention; Lu AG13909 that is in phase 1 clinical trial for neurohormonal dysfunctions; Brexpiprazole for post-traumatic stress disorder; Lu AF28996, which is in phase 1 clinical trial for Parkinson's disease; MAGLi program that is in phase 1 clinical trial for neurology; Bexicaserin, which is in phase 3 clinical trial for developmental and epileptic encephalopathies; Amlenetug that is in phase 3 clinical trial for synucleinopathies; and Lu AG22515, which is in clinical phase 1 clinical trial for neurology. Lundbeck A/S has a strategic research collaboration with Contera Pharma to develop oligonucleotide-based medicines for patients living with serious neurological conditions. The company was founded in 1915 and is headquartered in Valby, Denmark.
H Lundbeck A/S management
10- Mr. Charl van ZylPresident & CEO · born 1967
- Mr. Joerg HornsteinCFO & Executive VP of Corporate Functions · born 1977
- Dr. Per Johan Luthman Ph.D.Advisor · born 1959
- Dr. Tarek Samad Ph.D.Executive VP and Head of Research & Development
- Jens HoyerVice President & Head of Investor Relations
- Ms. Dianne HoltoExecutive Vice President of People, Culture & Sustainability · born 1973
- Mr. Thomas E. GibbsExecutive VP & Head of Lundbeck in United States · born 1971
- Prof. Johannes Rolf Streffer M.D.Senior VP & Head of Global Clinical Development · born 1969
- Ms. Michala Fischer-HansenExecutive VP and Head of Europe & International Markets and Operations · born 1974
- Ms. Tine Ostergaard HansenSenior Vice President of Corporate Affairs · born 1975